Download PDF

 

Former Veeva and ERT clinical trial technology executive will drive strategy towards a complete, tech-enabled biospecimen lifecycle solution

 

Slope, a global provider of biospecimen lifecycle software, data, and services for clinical trials, today announced that it has appointed Jim Munz to the role of Chief Product & Technology Officer. As CPTO, Munz will oversee the company's product and technology strategy to deliver and scale a fully tech-enabled biospecimen lifecycle solution for clinical trials.

 

Munz brings more than 25 years of expertise in product, technology, and operations — including 15 years specifically in clinical trials — to Slope. Most recently, he served as Chief Technology Officer - Digital Trials at Veeva, where he set the roadmap, built, and launched Veeva's digital platform for patient data acquisition within a year. Previously, Munz was VP of eCOA Product Management at ERT, where he established an innovation lab to explore how to safely incorporate new technologies into the highly regulated clinical trials industry.

 

"Our goal is to empower sponsors to take decisive action and make informed decisions about their trials using high-quality, real-time data about their samples," says Rust Felix, CEO at Slope. "Jim's addition to our executive team will drive continuous innovation in support of this vision and scale our product and technology functions to meet the growing demand for our solutions."

 

In his new role, Munz will spearhead Slope's product and technology strategy, overseeing the development and enhancement of the company's software solutions. He will work closely with the executive team, product managers, and customers to identify market opportunities, define product roadmaps, and ensure delivery of high-quality solutions that meet the evolving needs of clinical trials.

 

"I'm excited for the opportunity to work for an organization that is poised to have a meaningful impact on clinical trials," says Jim Munz, Chief Product & Technology Officer at Slope. "The biospecimen lifecycle is an exciting, but underserved space in our industry, with a direct impact on trial outcomes and patients. I look forward to driving innovation and offering sponsors a tech-enabled solution that delivers essential sample metadata while easing the burden on all trial stakeholders."

 

Source & Image Credit: Slope

 



Jim Munz, Slope CPTO, biospecimen lifecycle, clinical trials technology, tech-enabled solutions

Latest Articles

  • Most Regrettable Business Decisions

      Regrettable healthcare management decisions—errors, missed opportunities, and resource allocation pitfalls—can be profoundly costly and impactful. The ripple effects of such missteps can strain operational efficiency, compromise patient care, and erode the essential trust that underpins the re

    READ MORE
  • Why Do So Many Healthcare Innovation Initiatives Fail?

      Successful healthcare innovation requires more than technical and clinical expertise; it demands a deep understanding of the ecosystem, including regulatory requirements, reimbursement systems, and organisational dynamics. Embracing a holistic approach, fostering continuous feedback, and enga

    READ MORE
  • How Cultural Differences Can Make or Break Mergers and Acquisitions

      Organisational culture has a pivotal impact on M&A success. Neglecting cultural differences can lead to reduced productivity, operational hurdles, and strategic misalignments. Proactive strategies like cultural assessments and effective communication foster integration and enhance overal

    READ MORE
Jim Munz, Slope CPTO, biospecimen lifecycle, clinical trials technology, tech-enabled solutions, biospecimen management, clinical trial innovation Jim Munz joins Slope as CPTO to lead the development of tech-enabled biospecimen lifecycle solutions for clinical trials, driving strategy and innovation.